Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,800
Closed -$790K 1513
2025
Q3
$790K Buy
2,800
+2,700
+2,700% +$783K ﹤0.01% 1001
2025
Q2
$27.9K Sell
100
-178,100
-100% -$50.5M ﹤0.01% 1246
2025
Q1
$55.5M Buy
178,200
+157,100
+745% +$46.4M 0.52% 31
2024
Q4
$5.5M Sell
21,100
-35,600
-63% -$10.6M 0.05% 362
2024
Q3
$18.3M Buy
56,700
+46,700
+467% +$15.3M 0.15% 127
2024
Q2
$3.12M Hold
10,000
0.03% 436
2024
Q1
$2.84M Sell
10,000
-163,800
-94% -$47.9M 0.03% 468
2023
Q4
$50.1M Sell
173,800
-27,900
-14% -$7.6M 0.57% 29
2023
Q3
$54.2M Buy
201,700
+131,500
+187% +$32.8M 0.61% 28
2023
Q2
$15.6M Buy
+70,200
New +$16.3M 0.17% 134

Other funds holding AMGN

LMR Partners's AMGN Position: Q1 2026 in Review

LMR Partners sold out of Amgen (AMGN) in Q1 2026, closing a stake of 2 shares — an estimated $655 sold.

LMR Partners first reported a position in AMGN in Q4 2014 and held it in 29 quarters. The position peaked at $10.9M in Q4 2024. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • LMR Partners reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 2 Amgen shares in Q1 2026, an estimated $655.
  • LMR Partners first reported a position in Amgen in Q4 2014 and held it in 29 quarters.
  • LMR Partners's Amgen position peaked at $10.9M in Q4 2024.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.